Product Description
Mechanisms of Action: C-Met Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Lung Cancer|Liver Cancer
Phase 2: Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer|Renal Cell Carcinoma|Sarcoma|Clear Cell Sarcoma|Alveolar Soft Part Sarcoma|Seminoma|Hepatocellular Carcinoma|Head and Neck Cancer|Multiple Myeloma|Small Cell Lung Cancer|Melanoma|Breast Cancer|Squamous Cell Carcinoma|Ovarian Cancer|Oncology Unspecified|Pancreatic Cancer|Adenocarcinoma|Mesothelioma|Triple Negative Breast Cancer|Papillary Carcinoma|Prostate Cancer|Esophageal Cancer
Phase 1: Hepatocellular Carcinoma|Oncology Solid Tumor Unspecified|Small Cell Lung Cancer|Acute Respiratory Distress Syndrome|Melanoma|Liver Cirrhosis|Healthy Volunteers|Liver Cancer|Skin Cancer|Vascular Cancer|Non-Small-Cell Lung Cancer|Mouth Cancer|Ovarian Cancer|Soft Tissue Cancer|Hypoxia|Renal Cell Carcinoma|Kidney Diseases|NUT Carcinoma|Endometrial Cancer|Breast Cancer|Pancreatic Cancer|Cholangiocarcinoma|Sarcoma, Experimental|Gastrointestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2010-020151-31 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2019-01-14 |
|
| ARQ 197-299 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Hepatocellular Carcinoma|Ovarian Cancer|Renal Cell Carcinoma|Breast Cancer|Melanoma |
2019-01-14 |
|
| TIMES | P2 |
Terminated |
Small Cell Lung Cancer |
2018-07-31 |
|
| NCI-2012-01220 | P1 |
Completed |
Small Cell Lung Cancer |
2018-03-29 |